BCR-ABL positive CML patients expressing low morgana levels hardly achieve the major molecular response (MMR) after 18 months of treatment with the first line tyrosine kinase inhibitor imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.